論文（2015）

英文原著

  1. Ahihara E, Munaka T, Kimura S, Nakagawa S, Naakagawa Y, Kanai M, Hirai H, Abe H, Miida T, Yamato S, Shoji S, Maekawa T.　Isopentenyl Pyrophosphate Secreted from Zoledronate-Stimulated Myeloma Cells, Activates the Chemotaxis of γδ T Cells　Biochem Biophys Res Commun　2015
  2. Borthakur G, Duvvuri S, Ruvolo V, Tripathi DN, Piya S, Burks J, Jacamo R, Kojima K, Ruvolo P, Fueyo-Margareto J, Konopleva M, Andreeff M　MDM2 Inhibitor, Nutlin 3a, induces p53 dependent autophagy in acute leukemia by AMP kinase activation.　PLoS One. 10:e0139254　2015
  3. Harada M, Benito J, Yamamoto S, Kaur S, Arslan D, Ramirez S, Jacamo R, Platanias L, Matsushita H, Fujimura T, Kazuno S, Kojima K, Tabe Y, Konopleva M　The novel combination of dual mTOR inhibitor AZD2014 and pan-PIM inhibitor AZD1208 inhibits growth in acute myeloid leukemia via HSF pathway suppression.　Oncotarget 6:37930-47　2015
  4. Hosoya K, Mochinaga S, Emoto A, Yokoo H, Tokushima H, Egoshi M, Sueoka-Aragane N, Kimura S　Failure mode and effects analysis of medication adherence in patients with chronic myeloid leukemia.　Int J Clin Oncol  2015
  5. Imagawa J, Tanaka H, Okada M, Nakamae H, Hino M, Murai K, Ishida Y, Kumagai T, Sato S, Ohashi K, Sakamaki H, Wakita H, Uoshima N, Nakagawa Y, Minami Y, Ogasawara M, Takeoka T, Akasaka H, Utsumi T, Uike N, Sato T, Ando S, Usuki K, Morita S, Sakamoto J, Kimura S Discontinuation of dasatinib in chronic myeloid leukaemia patients who have maintained deep molecular response for more than 1 year: the prospective, multicentre Dasatinib Discontinuation (DADI) Trial.　Lancet Haematology　2015
  6. Ishizawa J, Kojima K, McQueen T, Ruvolo V, Chachad D, Nogueras-Gonzalez GM, Huang X, Pierceall WE, Dettman EJ, Cardone MH, Shacham S, Konopleva M, Andreeff M　Mitochondrial profiling of acute myeloid leukemia in the assessment of response to apoptosis modulating drugs.　PLoS One. 10:e0138377.　2015
  7. Matsuda K, Hattori S, Kariya R, Komizu Y, Kudo E, Goto H, Taura M, Ueoka R, Kimura S, Okada S.　Inhibition of HIV-1 entry by the tricyclic coumarin GUT-70 through the modification of membrane fluidity  Biochem Biophys Res Commun　2015
  8. Narita T, Inagaki A, Kobayashi T, Kuroda Y, Fukushima T, Nezu M, Fuchida S, Sakai H, Sekiguchi N, Sugiura I, Maeda Y, Takamatsu H, Tsukamoto N, Maruyama D, Kubota Y, Kojima M, Sunami K, Ono T, Ri M, Tobinai K, Iida S　t(14;16)-positive multiple myeloma shows negativity for CD56 expression and unfavorable outcome even in the era of novel drugs. 　Blood Cancer J. 5:e285　2015
  9. Nishida Y, Maeda A, Chachad D, Ishizawa J, Yi Hua Q, Kornblau SM, Kimura S, Andreeff M, Kojima K　Preclinical activity of the novel BMI-1 inhibitor PTC-209 in acute myeloid leukemia: implications for leukemia therapy.　Cancer Sci. 106:1705-1713.　2015
  10. Oubel E, Bonnard E, Sueoka-Aragane N, Kobayashi N, Charbonnier C, Yamamichi J, Mizobe H, Kimura S　Volume-based response evaluations with consensual lesion selection using cloud solutions (SaaS) in clinical trials: a pilot study　Academic Radiology　2015
  11. Sueoka-Aragane N, Katakami N, Satouchi M, Yokota S, Aoe K, Iwanaga K, Otsuka K, Morita S, Kimura S, Negoro S　For Hanshin-Saga Collaborative Cancer Study Group. Monitoring EGFR T790M with plasma DNA from lung cancer patients in a prospective observational study.　Cancer Sci　2015
  12. Sueoka-Aragane N, Kobayashi N, Bonnard E, Charbonnier C, Yamamichi J, Mizobe H, Kimura S　Evaluation of a cloud-based local-read paradigm for imaging evaluations in oncology clinical trials for lung cancer.　Acta Radiologica Open　2015
  13. *Tabe Y, Kojima K, Yamamoto S, Sekihara K, Matsushita H, Davis RE, Wang Z, Ma W, Ishizawa J, Kazuno S, Kauffman M, Shacham S, Fujimura T, Ueno T, Miida T, Andreeff M (equal contribution)　Ribosomal biogenesis and translational flux inhibition by the selective inhibitor of nuclear export (SINE) XPO1 antagonist KPT-185.　PLoS One. 10:e0137210　2015
  14. Umeguchi H, Sueoka-Aragane N, Kobayashi N, Nakamura T, Sato A, Takeda Y, Hayashi S, Sueoka E, Kimura S.　Usefulness of plasma HGF level for monitoring acquired resistance to EGFR tyrosine kinase inhibitors in non-small cell lung cancer　Oncol Rep　2015
  15. Yokoo M, Kubota Y, Motoyama K, Higashi T, Taniyoshi M, Tokumaru H, Nishiyama R, Tabe Y, Mochinaga S, Sato A, Sueoka-Aragane N, Sueoka E, Arima H, Irie T, Kimura S　2-Hydroxypropyl-β-cyclodextrin Acts as a Novel Anticancer Agent. 　PLoS One　2015
  16. Yokoo M, Kubota Y, Tabe Y, Kimura S　Comparative study of the anti-leukemic effects of imatinib mesylate, GlivecTM tablet and its generic formulation, OHK9511　Biol Pharma Bulletin　2015
  17. Watanabe T, Sato A, Kobayashi-Watanabe N, Sueoka-Aragane N, Kimura S, Sueoka E　Torin2 potentiates anti-cancer effects for adult T-cell leukemia/lymphoma by inhibiting mammalian target of rapamycin.         Anticancer Res    2015

英文症例報告、Letter to the editor

  1. Ando T, Kojima K, Isoda H, Eguchi Y, Honda T, Ishigami M, Kimura S　Reactivation of resolved infection with the hepatitis B virus immune escape mutant G145R during dasatinib treatment for chronic myeloid leukemia.　Int J Hematol　2015
  2. Kamachi K, Fukushima N, Ando T, Sato K, Ohshima K, Yokoo M, Shindo T, Kubota Y, Kojima K, Kimura S　Coexistence of ALK- anaplastic large cell lymphoma and CD4+ T cell large granular lymphocytic leukemia.　Ann Hematol 94; 539-540　2015
  3. Okada K, Kunitomi A, Sakai K, Muramushi H, Okamoto Y, Tsukamoto T, Sugiura H, Matsui H, Jo T, Ueda T, Onishi T, Takizawa J, Aoki S, Ide M, Kimura S　Notohara K, Ueda Y. Hairy cell leukemia with systemic lymphadenopathy: Detection of BRAF mutation in a lymph node specimen.　Int Med 2015
  4. Takahashi K, Inoue H, Sadamatsu H, Umeguchi H, Sueoka-Aragane N, Kimura S　A case of relapsing polychondritis successfully treated with combination of a glucocorticoid and cyclosporine.　Int J Clin Med　2015
  5. Ureshino H, Ando T, Kojima K, Itamura H, Jinnnai S, Doi Kazuko, Oshima K, Kurogi K, Miyahara M, Kimura S. 　Rituximab-containing chemotherapy (R-CHOP)-induced Kaposi’s sarcoma in an HIV-negative patient with diffuse large B cell lymphoma.　Intern Med　2015
  6. Ureshino H, Kadota C, Kurogi K, Miyahara M, Kimura S　Spontaneous regression of methotrexate related lymphoproliferative disorder with T cell large granular lymphocytosis.　 Int Med 2015

英文総説

  1. *Ishizawa J, Kojima K, Hail N Jr, Tabe Y, Andreeff M　Expression, function, and targeting of the nuclear exporter chromosome region maintenance 1 (CRM1) protein. Pharmacol Ther. 153:25-35　2015

英文著書

  1. Kojima K, Andreeff M　TP53.　Targeted Therapy in Translational Cancer Research, pp. 353-359　John Wiley & Sons. Hoboken, NJ, USA  2015

  2. Kojima K, Vassilev LT　Targeting p53 tumor suppressor for AML therapy.   Targeted Therapy of Acute Myeloid Leukemia, pp. 135-150　Springer, Berlin, Germany　2015

日本語原著

  1. 多良 明子, 鶴田 紀子, 三砂 範幸, 久保田 寧, 近藤 めぐみ, 成澤 寛    Glomeruloid Hemangioma 　西日本皮膚科 77(1):1-2　2015

日本語総説

  1. 安藤寿彦、木村晋也　高齢者の急性白血病の特徴とマネジメント　血液内科, 71(4); 437-442  2015
  2. 荒金尚子　血漿DNAを用いた肺がん遺伝子診断　Annual Review呼吸器2015, 155-161　2015
  3. 荒金尚子　血漿DNAを用いたEGFR-TKI獲得耐性モニタリング　日本胸部臨床 74 (6), 659-667 　2015
  4. 荒金尚子、小林直美、中島千穂、田代宏樹、貞松宏典　呼吸器抄読会　呼吸34, 629　2015
  5. 木村晋也　血液がん（慢性骨髄性白血病を中心に）　癌の臨床, 60(6):579-586   2014
  6. 木村晋也　慢性骨髄性白血病 (CML) に対するABLチロシンキナーゼ阻あら害剤の耐性メカニズム  医学の歩み, 252（7）:777-781 2015
  7. 木村晋也, 荒金尚子　V 慢性骨髄性白血病 (CML) 2. BCR-ABLの点突然変異の解析方法は？　白血病 Q&A（松村到編集）、中外医学社. P196-199　2015
  8. 小宮一利、荒金尚子　非小細胞肺がんの化学療法　臨牀と研究、92巻7号、861-865   2015
  9. 久保田 寧, 横尾 眞子, 木村 晋也   慢性骨髄性白血病治療の進歩とその成果　分子生物学的治療効果判定と第二世代(新規)TKIの選択  Medical Practice 32(2):299-303　2015
  10. 西岡敦二郎、木村晋也　T315Iに対する治療　慢性骨髄性白血病（CML）の基礎と臨床 医薬ジャーナル社P115-124　2015
  11. 進藤岳郎、木村晋也　多発性骨髄腫における免疫異常　日本臨牀、73(1): 52-61　2014
  12. 末岡榮三郎、木村晋也　輸血後鉄過剰症の現状と今後の展開　血液・腫瘍内科、70(3):343-348　2015

日本語著書

  1. 小島研介，木村晋也　"治療総論　分子標的治療薬"　Principles and Practice 血液・造血器・リンパ系　文光堂，東京　2015
  2. 小島研介　ゲムツズマブオゾガマイシン　新ABC　血液領域の分子標的治療薬　pp. 21-26　最新医学社　2015
  3. 久保田寧　1血液一般検査　C)凝固・線溶異常（凝固異常症の鑑別、凝固亢進型と線溶亢進型の評価と意義） 　日常診療のための検査値のみかた．13-18     中外医学社　2015
  4. 吉村麻里子　モガムリズマブ    "インフォームドコンセントのための図説シリーズ　悪性腫瘍薬 分子標的治療薬, 131-133"      医薬ジャーナル社　2015

最終更新日：2016年4月10日

(C)佐賀大学医学部附属病院血液・呼吸器・腫瘍内科